Open access · OA
via OpenAlex
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Chung, Robert Y. Kim
New England Journal of Medicine · 2006 · ▲ 5,856 citations
Abstract
BACKGROUND: Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration. METHODS: In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons). Visual acuity improved by 15 or more letters in 24.8% of the 0.3-mg group and 33.8% of the 0.5-mg group, as compared with 5.0% of the sham-injection group (P<0.001 for both doses). Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons). The benefit in visual acuity was maintained at 24 months. During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab. CONCLUSIONS: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836 [ClinicalTrials.gov].).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1056/nejmoa054481
- Canonical
- link ↗
- Fetched
- 2026-05-31 MST
Cite this
APA
Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C., & Kim, R.Y. (2006). Ranibizumab for Neovascular Age-Related Macular Degeneration. <em>New England Journal of Medicine</em>. https://doi.org/10.1056/nejmoa054481
Vancouver
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung C, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine. 2006. doi:10.1056/nejmoa054481.
BibTeX
@article{philip2006Ranibi,
title = {Ranibizumab for Neovascular Age-Related Macular Degeneration},
author = {Philip J. Rosenfeld and David M. Brown and Jeffrey S. Heier and David S. Boyer and Peter K. Kaiser and Carol Chung and Robert Y. Kim},
journal = {New England Journal of Medicine},
year = {2006},
doi = {10.1056/nejmoa054481},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
New England Journal of Medicine 2006
Citation only
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine 2004
Open access · OA
Pegaptanib for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine 2011
Open access · OA
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Novartis 2007
Open access · US-GOV
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months
Novartis Pharmaceuticals 2013
Open access · US-GOV
A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration
Clinical Interventions in Aging 2006
Open access · OA